Exhibit at CEU

Connect with more than 400 endocrinologists at Clinical Endocrinology Update (CEU) and Endocrine Board Review (EBR). Get your company's message out to practicing clinical endocrinologists and fellows. Learn more about exhibiting at CEU.

For more information contact:
Scott Zeller
856-302-0882
Scott_zeller@afassanoco.com

Exhibit at CEU Anaheim

CEU Anaheim Exhibitors

Corcept Therapeutics (Table 3)—Corcept Therapeutics is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Korlym® is the company’s first FDA-approved medication. Korlym inhibits the effects of excess cortisol in patients with hypercortisolism.

CEU 2018

Endocrine Society—Visit the Endocrine Society Store to purchase Society publications and merchandise at special CEU pricing. Items available for purchase include ESAP™ 2018, Pediatric ESAP™ 2017-2018, Meet-the-Professor 2018, apparel, and gifts for friends and family. You can also order the CEU 2018 Session Recordings at special attendee prices. Stop by to renew your Society membership for 2019 as well.

Gundersen Health System (Table 7)—Gundersen Health System, in La Crosse, Wisconsin, invites you to join us in our mission to deliver excellence in patient care, education, and research, and to improve health in the communities we serve. We are a physician-led, teaching organization, employing over 650 medical staff across all medical and surgical specialties.

Hormone Health Network—Visit the Hormone Health Network (HHN) booth for patient resources and to pick up the Diabetes Disaster Relief pocket guide. Share a patient FAQ for the chance to be featured on hormone.org.

HRA Pharma (Table 15)— Metopirone® (Metyrapone capsules 250mg) is a diagnostic drug for testing hypothalamic-pituitary ACTH function. Visit http://metopirone.us/ for more information.

Interpace Diagnostics (Table 14)—Interpace Diagnostics is a provider of molecular testing for numerous types of cancer. The Company offers ThyGeNEXT® and ThyraMIR® for indeterminate thyroid nodules; PancraGen® and PanDNA® for indeterminate pancreatic cysts; RespriDx® for differentiating metastasis from new primary lung tumors, and BarreGen® for Barrett’s esophagus, a precursor to esophageal cancer.

LeanMD (Table 5)—LeanMD can help achieve weight loss that is healthy and sustainable. Our program is founded on evidence-based medicine and scientifically backed nutrition principles.

CEU 2018

Novo Nordisk (Tables 10 & 11)—Novo Nordisk, a global health care company, is committed to discovering and developing innovative medicines to help people living with diabetes lead longer, healthier lives.

Pfizer (Table 8)—Our purpose is grounded in our commitment to fund programs that provide public benefit, advance medical care and improve patient outcomes. Our belief is that all people deserve to live healthy lives. This drives our desire to provide access to medicines that are safe, effective, and affordable.

Prader-Willi California Foundation —The success of people with Prader-Willi syndrome depends greatly upon the knowledge and support of the community around them. The Prader-Willi California Foundation provides individuals with PWS, their families and professionals with a state network of information, advocacy and support services.

Radius Health (Table 1)—Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. For more information, please visit www.radiuspharm.com.

Shire (Table 9)—Natpara is a parathyroid hormone indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.

Strongbridge BioPharma (Table 6)—Macrilen is the first and only FDA approved oral test for the diagnosis of Adult Growth Hormone Deficiency (AGHD).

Ultragenyx (Table 2)—Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases.